Puma Biotechnology (PBYI) Q3 2024 earnings summary

Executive summary

• Q3 2024 total revenue reached $80.5 million, up 43% year-over-year, with net product revenue of $56.1 million and royalty revenue of $24.4 million, both driven by strong China sales.

• Net income for Q3 2024 was $20.3 million GAAP ($0.41/share), reversing a net loss in Q2 and up from $5.8 million in Q3 2023; non-GAAP net income was $22.4 million ($0.45/share).

• Commercial focus remains on increasing NERLYNX utilization, especially in high-risk HER2-positive early-stage breast cancer patients, with ongoing global expansion and new sub-license agreements.

• Initiated Phase II trial for alisertib in small cell lung cancer; further breast cancer trial planned for Q4 2024.

• Positive operating cash flow and continued progress in clinical development of alisertib for cancer indications.

Financial highlights

• Q3 2024 product revenue was $56.1 million, up from $51.6 million in Q3 2023 and $44.4 million in Q2 2024; royalty revenue surged to $24.4 million from $4.5 million in Q3 2023, driven by China sales.

• SG&A expenses dropped to $16.8 million from $25 million in Q2 2024; R&D expenses were $12.5 million, down from $13.6 million.

• Cost of sales increased to $29.1 million, mainly due to timing of China sales.

• Gross-to-net adjustment improved to 17.1% from 20.4% in Q2 2024.

• Cash, cash equivalents, and marketable securities stood at $97 million as of September 30, 2024.

Outlook and guidance

• FY 2024 net product revenue for NERLYNX expected at $187–$190 million; Q4 guidance is $46–$48 million.

• FY 2024 royalty revenue projected at $34–$36 million; Q4 royalties at $3.5–$5 million.

• FY 2024 net income expected between $15–$17 million; Q4 net income guidance is $4–$6 million.

• Gross-to-net adjustment for FY 2024 anticipated at 20.5%–21.5%, higher than 2023 due to regulatory impacts.

• Key clinical milestones anticipated in 2024–2025 for alisertib in breast and lung cancer trials.